Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Nov;74(9):1354–1358. doi: 10.1038/bjc.1996.549

Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model.

S A Watson 1, T M Morris 1, S L Parsons 1, R J Steele 1, P D Brown 1
PMCID: PMC2074768  PMID: 8912529

Abstract

The matrix metalloproteinase inhibitor batimastat was administered to a human colorectal cancer ascites model, which was initiated by injection of C170HM2 cells into the peritoneal cavity of SCID mice and resulted in solid tumour deposits and ascites formation. The cell line expressed both the 72 and 92 kDa forms of gelatinase by zymography. Batimastat administered from day 0 (40 mg kg-1) reduced the volume of ascites to 21% of control in mice treated from day 0 (P < 0.002) but not day 10. Formation of solid peritoneal deposits was significantly reduced to 77% of vehicle control when batimastat was administered from day 0 (P < 0.01) and 69% of control when administered from day 10 (P < 0.05). Thus, batimastat has the ability to reduce the volume of ascites forming in SCID mice injected intraperitoneally with the human colorectal cell line, C170HM2, when administered from day 0 but not from day 10. Solid peritoneal tumour deposits were significantly reduced in both treatment groups, highlighting the therapeutic potential of batimastat in this clinical condition.

Full text

PDF
1354

Images in this article

1355Figure 1
on p.1355

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown P. D., Bloxidge R. E., Stuart N. S., Gatter K. C., Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst. 1993 Apr 7;85(7):574–578. doi: 10.1093/jnci/85.7.574. [DOI] [PubMed] [Google Scholar]
  2. Chirivi R. G., Garofalo A., Crimmin M. J., Bawden L. J., Stoppacciaro A., Brown P. D., Giavazzi R. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer. 1994 Aug 1;58(3):460–464. doi: 10.1002/ijc.2910580326. [DOI] [PubMed] [Google Scholar]
  3. D'Errico A., Garbisa S., Liotta L. A., Castronovo V., Stetler-Stevenson W. G., Grigioni W. F. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Mod Pathol. 1991 Mar;4(2):239–246. [PubMed] [Google Scholar]
  4. Davies B., Brown P. D., East N., Crimmin M. J., Balkwill F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 1993 May 1;53(9):2087–2091. [PubMed] [Google Scholar]
  5. Jeziorska M., Haboubi N. Y., Schofield P. F., Ogata Y., Nagase H., Woolley D. E. Distribution of gelatinase B (MMP-9) and type IV collagen in colorectal carcinoma. Int J Colorectal Dis. 1994 Aug;9(3):141–148. doi: 10.1007/BF00290191. [DOI] [PubMed] [Google Scholar]
  6. Lobb R. R., Key M. E., Alderman E. M., Fett J. W. Partial purification and characterization of a vascular permeability factor secreted by a human colon adenocarcinoma cell line. Int J Cancer. 1985 Oct 15;36(4):473–478. doi: 10.1002/ijc.2910360410. [DOI] [PubMed] [Google Scholar]
  7. McDonnell S., Navre M., Coffey R. J., Jr, Matrisian L. M. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog. 1991;4(6):527–533. doi: 10.1002/mc.2940040617. [DOI] [PubMed] [Google Scholar]
  8. Newell K. J., Witty J. P., Rodgers W. H., Matrisian L. M. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog. 1994 Aug;10(4):199–206. doi: 10.1002/mc.2940100404. [DOI] [PubMed] [Google Scholar]
  9. Porte H., Chastre E., Prevot S., Nordlinger B., Empereur S., Basset P., Chambon P., Gespach C. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer. 1995 Feb 20;64(1):70–75. doi: 10.1002/ijc.2910640114. [DOI] [PubMed] [Google Scholar]
  10. Poulsom R., Pignatelli M., Stetler-Stevenson W. G., Liotta L. A., Wright P. A., Jeffery R. E., Longcroft J. M., Rogers L., Stamp G. W. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol. 1992 Aug;141(2):389–396. [PMC free article] [PubMed] [Google Scholar]
  11. Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Harvey V. S., Dvorak H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983 Feb 25;219(4587):983–985. doi: 10.1126/science.6823562. [DOI] [PubMed] [Google Scholar]
  12. Senger D. R., Perruzzi C. A., Feder J., Dvorak H. F. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 1986 Nov;46(11):5629–5632. [PubMed] [Google Scholar]
  13. Taraboletti G., Garofalo A., Belotti D., Drudis T., Borsotti P., Scanziani E., Brown P. D., Giavazzi R. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst. 1995 Feb 15;87(4):293–298. doi: 10.1093/jnci/87.4.293. [DOI] [PubMed] [Google Scholar]
  14. Wang X., Fu X., Brown P. D., Crimmin M. J., Hoffman R. M. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994 Sep 1;54(17):4726–4728. [PubMed] [Google Scholar]
  15. Watson S. A., Morris T. M., Crosbee D. M., Hardcastle J. D. A hepatic invasive human colorectal xenograft model. Eur J Cancer. 1993;29A(12):1740–1745. doi: 10.1016/0959-8049(93)90117-x. [DOI] [PubMed] [Google Scholar]
  16. Watson S. A., Morris T. M., Robinson G., Crimmin M. J., Brown P. D., Hardcastle J. D. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res. 1995 Aug 15;55(16):3629–3633. [PubMed] [Google Scholar]
  17. Zucker S., Lysik R. M., Zarrabi M. H., Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993 Jan 1;53(1):140–146. [PubMed] [Google Scholar]
  18. van der Stappen J. W., Hendriks T., Wobbes T. Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors. Int J Cancer. 1990 Jun 15;45(6):1071–1078. doi: 10.1002/ijc.2910450616. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES